Members

Pierre Caudrelier, MD

Chief Medical Officer, Theratechnologies Inc.

Responsible for all preclinical, clinical, regulatory and pharmaceutical development activities, Dr. Pierre Caudrelier joined Theratechnologies in 2007.

Experienced in the area of immunology and immunotherapies, Dr. Caudrelier spent most of his career leading the clinical research and development of products such as: vaccines, cell-based immunotherapies, monoclonal antibodies, live recombinant viral vectors, recombinant proteins, small molecules and peptides in both prophylactic and therapeutic indications. He has been involved in all aspects of clinical development (Phase 1-4) including the interaction with regulatory bodies and international agencies worldwide including Europe and North America.

For over 15 years, Dr. Caudrelier held various positions at Aventis Pasteur (now Sanofi Aventis) ending his career there in the position of Clinical Program Director, HIV Program. In this role he was responsible for clinical development of certain HIV products and, at the time of his departure, was responsible for over 40 clinical trials including the preparation of two large Phase 3 trials in Thailand and the Americas.

Dr. Caudrelier was recently Vice-President, Clinical Research & Chief Medical Officer at Kiadis Pharma where he led the clinical development on four proprietary products in the area of oncology. Previously, Dr. Caudrelier was at Immuno-Designed Molecules (I.D.M. Biotech) as Vice President, Scientific and Medical Affairs where he equally led the clinical research and development aspects for this company.